Type 2 Diabetes

>

Latest News

Elena Christofides, MD | Credit: Endocrinology Associates
Insulin Glargine Biosimilar Demonstrates Bioequivalence to Originator for Type 2 Diabetes

April 13th 2024

The proposed insulin glargine biosimilar (Basalin) showed comparable immunogenicity, efficacy, and safety to the originator (Lantus) in a phase 3 equivalence trial.

Manufacturing Costs for Diabetes Medicines Could Likely Be Lower | Image Credit: Harvard University
Manufacturing Costs for Diabetes Medicines Could Likely Be Lower, Study Finds

April 4th 2024

Endocrinology Month in Review: March 2024 thumbnail featuring HCOLive endocrinology logo
Endocrinology Month in Review: March 2024

April 3rd 2024

Credit: US Food and Drug Administration
Semaglutide (Wegovy) Receives FDA Label Expansion to Include Cardiovascular Risk Reduction

March 8th 2024

Stock imagery of a body weight scale. | Credit: iStock
Novo Nordisk Delivers Updates on Development of Semaglutide, CagriSema, Amycretin, and More

March 7th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.